- Home
- IBRX vs HBI Comparison
IBRX vs HBI Comparison
Compare IBRX & HBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- HBI
- Stock Information
- Founded
- IBRX 2014
- HBI 1901
- Country
- IBRX United States
- HBI United States
- Employees
- IBRX N/A
- HBI N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- HBI Clothing/Shoe/Accessory Stores
- Sector
- IBRX Health Care
- HBI Consumer Discretionary
- Exchange
- IBRX Nasdaq
- HBI Nasdaq
- Market Cap
- IBRX 2.3B
- HBI 1.9B
- IPO Year
- IBRX N/A
- HBI 2006
- Fundamental
- Price
- IBRX $2.81
- HBI $4.63
- Analyst Decision
- IBRX Strong Buy
- HBI Hold
- Analyst Count
- IBRX 5
- HBI 4
- Target Price
- IBRX $11.40
- HBI $5.75
- AVG Volume (30 Days)
- IBRX 7.3M
- HBI 4.5M
- Earning Date
- IBRX 08-11-2025
- HBI 08-07-2025
- Dividend Yield
- IBRX N/A
- HBI N/A
- EPS Growth
- IBRX N/A
- HBI N/A
- EPS
- IBRX N/A
- HBI N/A
- Revenue
- IBRX $31,222,000.00
- HBI $3,522,911,000.00
- Revenue This Year
- IBRX $567.98
- HBI $0.50
- Revenue Next Year
- IBRX $160.56
- HBI N/A
- P/E Ratio
- IBRX N/A
- HBI N/A
- Revenue Growth
- IBRX 10238.41
- HBI 0.65
- 52 Week Low
- IBRX $1.83
- HBI $4.02
- 52 Week High
- IBRX $7.48
- HBI $9.10
- Technical
- Relative Strength Index (RSI)
- IBRX 51.33
- HBI 45.90
- Support Level
- IBRX $2.68
- HBI $4.57
- Resistance Level
- IBRX $3.00
- HBI $4.80
- Average True Range (ATR)
- IBRX 0.16
- HBI 0.17
- MACD
- IBRX -0.00
- HBI 0.02
- Stochastic Oscillator
- IBRX 62.00
- HBI 58.71
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About HBI Hanesbrands Inc.
Hanesbrands manufactures basic and athletic apparel under brands including Hanes, Playtex, Maidenform, Bali, Berlei, and Bonds. The company sells wholesale to discount, midmarket, and department store retailers as well as direct to consumers through stores and e-commerce. Hanesbrands is vertically integrated as it produces nearly 75% of its products in company-controlled factories in more than three dozen nations. Hanesbrands distributes products in the Americas and Asia-Pacific. The company was founded in 1901 and is based in Winston-Salem, North Carolina.